Healthcare · Profile from Healthcare Research Companion
Roche Holding AG
The Basel-based, family-controlled group that is both one of the world's largest pharmaceutical companies and the world's largest in-vitro diagnostics company. Roche's modern shape comes from two very different bets: buying majority control of the Californian biotech pioneer Genentech in 1990 (and the rest in 2009), which made it the leader in cancer antibodies, and buying Boehringer Mannheim in 1997–98, which made it the leader in lab diagnostics. It pairs a long record of scientific success with notable failures: the Seveso dioxin disaster (1976), the 1999 vitamin cartel, write-offs on Spark Therapeutics and Flatiron Health, and a string of late-stage trial misses.
At a glance
- Founded
- 1 October 1896, Basel, Switzerland, as F. Hoffmann-La Roche & Co.
- Founders
- Fritz Hoffmann-La Roche (1868–1920), a Basel merchant's son; chemist Carl Schaerges and others built the early product line
- Headquarters
- Basel, Switzerland; Genentech in South San Francisco is the US pharma hub; Roche Diagnostics in Rotkreuz (Switzerland), Mannheim and Penzberg (Germany), Indianapolis and Pleasanton/Tucson (US)
- Ownership / structure
- Listed on SIX Swiss Exchange: voting bearer shares (RO) and non-voting dividend-right certificates (Genussscheine, ROG). A founding-family pool (Hoffmann and Oeri descendants) controls just over half of the voting shares after Roche bought back Novartis's ~33% voting stake in 2021 (reported, verify exact percentage)
- Leadership (2026)
- Thomas Schinecker, CEO since March 2023 (previously head of Diagnostics); Severin Schwan, chairman since March 2023 (CEO 2008–2023); Teresa Graham, CEO Pharmaceuticals (from 2023, reported); Matt Sause, CEO Diagnostics (from 2023, reported)
- Segment and buyer
- Pharma (oncology, neuroscience, immunology, ophthalmology, haematology, obesity pipeline) paid by public and private insurers worldwide; Diagnostics (analyzers and reagents for central labs, molecular, point of care, pathology, diabetes care) sold to hospital and reference labs
- Scale
- 2025 group sales CHF ~61.5bn (+7% at constant exchange rates, +2% in CHF); Pharmaceuticals CHF ~47.7bn, Diagnostics CHF ~13.8bn; core operating profit CHF ~21.8bn (reported); ~100,000+ employees (verify)
- Capital / market cap
- Self-financed with investment-grade debt; market capitalisation roughly CHF 200–250bn in 2025–26 (verify)
- Signature moves (incl. failures)
- Founding (1896); vitamin C and Valium eras; Seveso disaster (1976); Genentech majority (1990) and full purchase (2009, ~$46.8bn); Boehringer Mannheim (1997–98, ~$11bn); vitamin cartel guilty plea (1999); Flatiron and Foundation Medicine (2018); Spark Therapeutics (2019, written off 2024–25); Novartis stake buyback (2021, ~$20.7bn); obesity bets via Carmot and Zealand (2023–25)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1896
Founding Hoffmann La Roche
Founding
1976
Seveso Dioxin Disaster
Industrial accident / liability and crisis response
1997
Boehringer Mannheim Diagnostics
Acquisition
1999
Vitamin Cartel Guilty Plea
Regulatory settlement / criminal plea
2009
Genentech Full Acquisition
Acquisition (of the remaining minority; preceded by a 1990 majority purchase)
2018
Flatiron and Foundation Medicine
Acquisition / data strategy
2019
Spark Therapeutics Acquisition
Acquisition / write-down / restructuring
2023
Obesity Bet Carmot and Zealand
Acquisition and partnership